Passage BIO, Inc. (PASG): Nasdaq/NYSE listing notice — Passage Bio transfers listing to Nasdaq Capital Market; granted 180-day extension to meet $1.00 bid price

Passage BIO, Inc.

Received Nasdaq deficiency notice on Aug 1, 2024 for bid price below $1.00 for 30 consecutive days.
Nasdaq approved transfer to Capital Market effective Jan 30, 2025; stock continues trading under PASG.
Granted additional 180-day compliance period until July 28, 2025 to regain $1.00 minimum bid price.
Company will monitor and consider options including reverse stock split if necessary.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Passage BIO, Inc. received a nasdaq extension granted notice regarding minimum bid price.

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price

Exact text from the filing

January 29, 2025, the Nasdaq Listing Qualifications department approved the Company’s request to transfer the listing of the Company’s shares of common stock from The Nasdaq Global Select Market to The Nasdaq Capital Mar

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Passage BIO, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price.

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price

Exact text from the filing

August 1, 2024, Passage Bio, Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company was not in compliance with certain of Nasdaq’s continued listing requirements, as the closing bid price of the Company’s shares had been below $1.00 per share for the previous 30 consecutive business days. The Company was given a period of 180 calendar days, or until January 28, 2025, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its shares from The Nasdaq Globa

View on SEC.gov

Browse all listing & compliance notices →

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-008100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.